SIRION Biotech Licenses its LentiBOOST™ Transduction Technology to Cellectis
Through this license agreement, SIRION Biotech GmbH granted Cellectis non-exclusive right under its proprietary lentiviral transduction enhancer LentiBOOST™....
SIRION Biotech was thrilled to receive its trophy after winning a Gold Stevie Award at this year’s American Business Awards, winning in the category Fastest Growing Company of the Year – Up to 100 Employees, after achieving record growth in the previous year.
SIRION Biotech is a globally active technology provider with a strong customer base in the fields of cancer research, neurosciences, regenerative medicines, gene therapy, CAR T-cell development and R&D of new vaccination methods.
Founded in 2007 at the IZB in Martinsried near Munich, Germany, the company was designed to shift the paradigm of viral vector technologies and supplies.
For more information, please fill out the enquiry form attached to this page.
Through this license agreement, SIRION Biotech GmbH granted Cellectis non-exclusive right under its proprietary lentiviral transduction enhancer LentiBOOST™....
Mustang Bio Inc (Mustang) and SIRION Biotech GmbH (SIRION) are pleased that Mustang has acquired...
The Bavarian Research Foundation has recognised the development being made in continuous research by SIRION...
SIRION Biotech provides highly advanced viral vector technology, as well as vector manufacturing platforms established...